BTIG Research Reaffirms Buy Rating for Organogenesis (NASDAQ:ORGO)

Organogenesis (NASDAQ:ORGO)‘s stock had its “buy” rating reaffirmed by equities researchers at BTIG Research in a research note issued to investors on Monday,Benzinga reports. They presently have a $9.00 price objective on the stock. BTIG Research’s price objective would suggest a potential upside of 86.34% from the company’s previous close.

Several other research firms also recently weighed in on ORGO. Wall Street Zen raised shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Organogenesis in a report on Monday, December 8th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.00.

Organogenesis Price Performance

NASDAQ:ORGO opened at $4.83 on Monday. The stock has a 50 day moving average of $4.77 and a two-hundred day moving average of $4.46. Organogenesis has a 12 month low of $2.61 and a 12 month high of $7.08. The firm has a market cap of $612.98 million, a P/E ratio of -40.25 and a beta of 1.47. The company has a current ratio of 3.32, a quick ratio of 2.88 and a debt-to-equity ratio of 0.01.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. Organogenesis had a positive return on equity of 4.01% and a negative net margin of 1.30%.The company had revenue of $150.86 million for the quarter, compared to analyst estimates of $134.10 million. On average, analysts expect that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Insider Transactions at Organogenesis

In related news, Director Glenn H. Nussdorf sold 187,957 shares of the firm’s stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $5.29, for a total transaction of $994,292.53. Following the completion of the sale, the director directly owned 2,765,591 shares in the company, valued at approximately $14,629,976.39. This trade represents a 6.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 300,000 shares of company stock worth $1,592,120 in the last ninety days. 33.00% of the stock is currently owned by company insiders.

Institutional Trading of Organogenesis

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Organogenesis by 23.4% during the 1st quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock valued at $19,144,000 after buying an additional 841,618 shares during the period. Invesco Ltd. raised its position in Organogenesis by 779.7% in the first quarter. Invesco Ltd. now owns 1,069,252 shares of the company’s stock valued at $4,619,000 after purchasing an additional 947,705 shares during the period. Nuveen LLC purchased a new stake in Organogenesis in the first quarter valued at $742,000. Russell Investments Group Ltd. acquired a new position in shares of Organogenesis in the 1st quarter valued at $547,000. Finally, American Century Companies Inc. increased its position in shares of Organogenesis by 32.7% during the 1st quarter. American Century Companies Inc. now owns 131,220 shares of the company’s stock worth $567,000 after purchasing an additional 32,328 shares during the last quarter. Institutional investors and hedge funds own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.